Biopharma Services Usa Inc.

What Biopharma Services Usa Inc. does

BioPharma Services Inc., operating under the BioPharma Services USA Inc. entity, is a private, full-service Contract Research Organization specializing in early-phase clinical research and bioanalytical services for pharmaceutical and biotechnology drug development sponsors. Core offerings span Phase 1/2a clinical trials (First-in-Human, Single and Multiple Ascending Dose, proof-of-concept, food-effect), bioequivalence and bioavailability studies supporting generic and 505(b)(2) NDA filings, human abuse potential studies for opioids, narcotics, and cannabinoids, and LC/MS/MS-based bioanalysis. Specialty service lines include psychedelic clinical trials (psilocybin and psilocin) and PET CNS first-in-human neuroimaging, supported by integrated biometrics, CDISC-compliant data management, clinical biostatistics, medical writing, scientific affairs, pharmacokinetics, and subject recruitment.

The company operates clinical facilities in Toronto, Ontario (Canadian headquarters and main research clinic) and St. Louis, Missouri (US facility relocated from Columbia), with combined 150-bed capacity. The underlying technology stack includes state-of-the-art LC/MS/MS bioanalytical platforms with proprietary assay and extraction methods, CDISC-compliant data standards integrated through submission, and the clinicalRSVP biometric fingerprint system for real-time dual-enrollment prevention. BioPharma has passed 35+ regulatory inspections across the US FDA, UK MHRA, French ANSM, Danish DKMA, Brazilian ANVISA, and Health Canada, holds GLP certification from the Standards Council of Canada, and maintains PHIPA, PIPEDA, and GDPR compliance.

Revenue is generated through contract-based professional services to pharmaceutical and biotechnology sponsors in Canada, the United States, and Europe, accessed via direct enterprise sales and discovery-call inquiries on the company website. Volunteer participants are recruited through phone/text outreach, a maintained healthy-volunteer database, and a referral program offering $200 standard and $500 select-study incentives, with trial compensation ranging $1,000-$4,000 depending on study design. Marketing leverages content (blog, scientific corner), LinkedIn, YouTube, and email newsletters. Leadership includes CEO Renzo G. DiCarlo, CSO Dr. John Oldenhof, CCO Amarjit Girn, and Chief Compliance Officer Vaideki Dharmaratnam.

Name

Biopharma Services Usa Inc.

Legal name

BioPharma Services Inc.

Website

https://biopharmaservices.com

Company type

Private

Operating status

Operating

Short description

BioPharma Services Inc. is a private, full-service Phase 1 Contract Research Organization providing early-phase clinical trials, bioequivalence/bioavailability studies, human abuse potential research, and LC/MS/MS bioanalysis to pharmaceutical and biotechnology sponsors across North America and Europe.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF)

Keywords

• Clinical research services
• Bioequivalence studies
• Early phase clinical trials
• Bioanalytical testing
• Pharmacokinetic studies

Headquarters

HQ city

Creve Coeur

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Clinical Research Services: BioPharma Services generates revenue as a contract research organization providing Phase I-IIa clinical trials, bioequivalence/bioavailability studies, bioanalysis, and related scientific services to pharmaceutical and biotechnology sponsors on a contract basis.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

BioPharma Services USA Inc. is a full-service Contract Research Organization (CRO) that conducts early-phase clinical trials and bioanalytical services for pharmaceutical and biotechnology drug development sponsors. The company's core offerings include Phase 1/2a clinical trials, bioequivalence and bioavailability studies, human abuse potential studies, and bioanalysis using LC/MS/MS platforms, delivered from clinical facilities in Toronto, Canada and St. Louis, USA.

Product overview

BioPharma Services Inc. is a full-service Contract Research Organization (CRO) providing clinical research services. The company's portfolio consists of Phase 1/2a clinical trials as its core product, complemented by bioequivalence and bioavailability studies, human abuse potential studies, and bioanalysis services. Supporting these core offerings is a suite of services including biometrics/CDISC-compliant data management, medical writing, scientific affairs, pharmacokinetics, and subject recruitment. Specialty services include PET clinical trials and neuroimaging, as well as psychedelic clinical trials. The company operates from clinical facilities in Toronto, Ontario and St. Louis, Missouri.

Differentiator

Problem solved

Functional benefit

Products and services

• Phase 1 Clinical Trials Early-phase clinical trial services conducted across multiple therapeutic areas, including First-in-Human (FIH), Single Ascending Dose (SAD), Multiple Ascending Dose (MAD), proof of concept studies, and food effect studies for pharmaceutical and biotechnology sponsors.
• Bioequivalence and Bioavailability Studies BE/BA studies to support both generic and hybrid drug filings and 505(b)(2) New Drug Applications, including adaptive sequential design and study coordination for generic drug approvals.
• Human Abuse Potential Studies Clinical studies in opioids, narcotics and cannabinoid products to help drug developers understand their product's potential risk for abuse before seeking regulatory approval, including abuse deterrent formulation assessments.
• Bioanalysis and Bioanalytical Services High quality, accurate and innovative bioanalytical solutions using LC/MS/MS platforms for detecting drugs in biological samples, including novel assay and extraction method development, bioanalytical method validation, and assay services.
• PET Clinical Trials and Neuroimaging Positron Emission Tomography CNS first-in-human trials and molecular imaging services, including coordination between clinical and imaging sites for neuroscience drug development.
• Psychedelic Clinical Trials Clinical trials involving psychedelics including high and microdosing studies, with expertise in psilocybin and psilocin methodology for CNS drug development.
• Pharmacokinetics Studies PK studies evaluating drug absorption, distribution, metabolism and excretion under leadership of Chief Scientific Officer Dr. John Oldenhof, supporting drug submissions to multiple regulatory markets.
• Scientific Affairs Expert consultation on clinical drug development programs across multiple therapeutic areas for pharmaceutical and biotechnology sponsors.
• Clinical Trial Data Management Efficient, cost-effective data management services meeting current regulatory and industry standards for clinical drug development programs.
• Biometrics and CDISC Services Biostatistical services with CDISC data standards compliance for clinical drug development and regulatory submissions to FDA and other regulatory markets.
• Medical Writing Medical writing services ensuring clear communication between subjects, sites, sponsors and regulatory agencies across clinical drug development programs.
• Clinical Biostatistics Statistical analysis services for clinical trial design and evaluation across drug development programs.
• Functional Services Provider (FSP) Flexible staffing and consulting services for clinical trial support, including FSP consulting engagements for sponsor organizations.
• Subject Recruitment Clinical trial recruitment services with an extensive database of engaged healthy volunteers including special populations for bioequivalence and Phase 1 studies.

Quantifiable outcome

• 2,500+ bioequivalence and Phase I clinical trials conducted
• +2 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature3 records

Partnerships

Two partnerships are on record, tiered core and parent.

• clinicalRSVPcoreTechnology or IntegrationclinicalRSVP provides biometric fingerprint technology for real-time authentication of clinical trial participants to prevent dual enrollment. This system is used during the screening process at BioPharma facilities to ensure research integrity.
• Think Research CorporationparentOthersBioPharma Services Inc. is identified as a Think Research Corporation company on their blog, indicating Think Research as the parent company or significant investor.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Labcorp Drug Development (Fortrea): Labcorp Drug Development (now Fortrea) operates one of the largest early-phase clinical and bioanalytical networks globally, a broad incumbent that sets pricing and capacity benchmarks for BioPharma.
• Charles River Laboratories: Charles River is a large, diversified CRO with broad Phase I and bioanalytical offerings; BioPharma competes in the same end markets but at much smaller scale and narrower scope.
• IQVIA: IQVIA is the largest global CRO with end-to-end clinical development services including early-phase units, representing the upper-end incumbent that BioPharma benchmarks against but cannot match in scale or scope.
• Syneos Health: Syneos Health is a global biopharmaceutical services organization offering clinical and commercial solutions, overlapping with BioPharma's Phase I offerings as part of a much broader portfolio.
• PAREXEL: PAREXEL is a long-established global CRO with Phase I and bioanalytical services, representing a comparable yet much larger incumbent across the same early-phase client base.

Direct peers

• Frontage Laboratories: Frontage Laboratories provides bioanalytical and early-phase clinical services including bioequivalence, closely overlapping with BioPharma's core offerings in LC/MS/MS bioanalysis and BE/BA studies.
• Celerion: Celerion is a specialized early-phase clinical research and bioanalytical CRO offering Phase I studies, bioequivalence, and human abuse liability services — a direct competitor in the same niche as BioPharma.
• Medpace: Medpace is a mid-sized full-service CRO with Phase I capabilities, competing for early-phase work alongside BioPharma, though with broader geographic reach.
• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-tier CRO with strong early-phase and bioanalytical capabilities, often competing head-to-head with BioPharma for Phase 1 and bioequivalence sponsors.
• Altasciences: Altasciences is a mid-sized Phase 1 CRO with bioanalytical and bioequivalence capabilities across North America, directly comparable to BioPharma Services in early-phase clinical and BE/BA service lines.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCuMfcBpHgI8mJQhs872ycmg/featured
• LinkedInca.linkedin.com/company/biopharma-services-inc

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biopharma Services Usa Inc.